Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
401
Recruiting Now
401
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT07826689 Phase 1, Phase 2
Recruiting
A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relaps...
Condition
Multiple Sclerosis
Enrollment
160 pts
Location
Australia
Sponsor
Progentos Therapeutics
NCT06424340 Phase 1, Phase 2
Recruiting
MB-dNPM1-TCR.1 in Relapsed/Refractory AML
Condition
Leukemia, Myeloid, Acute
Enrollment
29 pts
Location
Netherlands
Sponsor
Miltenyi Biomedicine GmbH
NCT07513038 Phase 1, Phase 2
Recruiting
Use of Indocyanine Green (ICG) for the Diagnosis of Biliary Atresia
Condition
Biliary Atresia
Enrollment
20 pts
Location
United States
Sponsor
Boston Children's Hospital
NCT07479485 Phase 1, Phase 2
Recruiting
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
Condition
Hepatocellular Carcinoma
Enrollment
160 pts
Location
China
Sponsor
Lepu Biopharma Co., Ltd.
NCT06868849 Phase 1, Phase 2
Recruiting
A Study of JMT203 in Patients With Cancer Cachexia
Condition
Non Small Cell Lung Cancer
Enrollment
307 pts
Location
China
Sponsor
Shanghai JMT-Bio Inc.
NCT05187338 Phase 1, Phase 2
Recruiting
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Condition
Lung Cancer
Enrollment
100 pts
Location
China
Sponsor
Second Affiliated Hospital of
NCT06385925 Phase 1, Phase 2
Recruiting
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G...
Condition
Malignant Neoplasm
Enrollment
440 pts
Location
United States, China
Sponsor
Tyligand Pharmaceuticals (Suzh
NCT07563738 Phase 1, Phase 2
Recruiting
A 2-part Phase 1/2 Open-label Trial on ODM-212
Condition
Mesothelioma
Enrollment
229 pts
Location
United States, Denmark, Finland
Sponsor
Orion Corporation, Orion Pharm
NCT07387926 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Ref...
Condition
Acute Lymphoblastic Leukemia
Enrollment
50 pts
Location
Australia, France, Israel
Sponsor
Novartis Pharmaceuticals
NCT06987916 Phase 1, Phase 2
Recruiting
Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma
Condition
B Cell Lymphoma
Enrollment
50 pts
Location
China
Sponsor
Shanghai Tongji Hospital, Tong
NCT06378593 Phase 1, Phase 2
Recruiting
A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With...
Condition
Solid Tumors With FGFR2 Alterations, Adult
Enrollment
130 pts
Location
China
Sponsor
3H (Suzhou) Pharmaceuticals Co
NCT06895733 Phase 1, Phase 2
Recruiting
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co...
Condition
Solid Tumor, Adult
Enrollment
65 pts
Location
China
Sponsor
Tianjin Medical University Sec
NCT06642792 Phase 1, Phase 2
Recruiting
A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymp...
Condition
Classic Hodgkin Lymphoma
Enrollment
280 pts
Location
China
Sponsor
Akeso
NCT07474467 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy...
Condition
Atrophic Scar
Enrollment
31 pts
Location
South Korea
Sponsor
CellinCells
NCT06783309 Phase 1, Phase 2
Recruiting
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Wit...
Condition
Type 1 Diabetes Mellitus
Enrollment
72 pts
Location
United States
Sponsor
COUR Pharmaceutical Developmen
NCT06538584 Phase 1, Phase 2
Recruiting
Dex +/- Caffeine Sedation in a Post-MRI Recovery in a Pediatric Population
Condition
Enhanced Recovery After Surgery in a Pediatric Population
Enrollment
100 pts
Location
United States
Sponsor
University of Chicago
NCT06341400 Phase 1, Phase 2
Recruiting
RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible M...
Condition
Bladder Cancer
Enrollment
55 pts
Location
China
Sponsor
Zhujiang Hospital
NCT07831798 Phase 1, Phase 2
Recruiting
VV-14300 for the Treatment of Type 1 Diabetes
Condition
Type 1 Diabetes Mellitus
Enrollment
29 pts
Location
Canada, New Zealand
Sponsor
Kriya Therapeutics, Inc.
NCT07281716 Phase 1, Phase 2
Recruiting
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastati...
Condition
Metastatic Microsatellite Stable Colorectal Carcinoma
Enrollment
24 pts
Location
United States
Sponsor
Dan Feng
NCT06298916 Phase 1, Phase 2
Recruiting
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Condition
Metastatic Sarcoma
Enrollment
26 pts
Location
United States
Sponsor
Lantheus Medical Imaging
NCT07024316 Phase 1, Phase 2
Recruiting
A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesi...
Condition
Congenital Erythropoietic Porphyria (CEP)
Enrollment
6 pts
Location
United States
Sponsor
Atlas Molecular Pharma
NCT06106906 Phase 1, Phase 2
Recruiting
A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
Condition
Systemic Lupus Erythematosus
Enrollment
15 pts
Location
China
Sponsor
Union Hospital, Tongji Medical
NCT05419492 Phase 1, Phase 2
Recruiting
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Ch...
Condition
Dravet Syndrome
Enrollment
113 pts
Location
United States, Australia, United Kingdom
Sponsor
Encoded Therapeutics
NCT06572514 Phase 1, Phase 2
Recruiting
De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC
Condition
Locally Advanced Head and Neck Squamous Cell Carcinoma
Enrollment
20 pts
Location
China
Sponsor
Ruijin Hospital
NCT06817863 Phase 1, Phase 2
Recruiting
A Self-Guided Mobile Intervention for Adults With Binge Eating and Obesity
Condition
Binge Eating Disorder Associated With Obesity
Enrollment
30 pts
Location
United States
Sponsor
Drexel University
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology